{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:41:42Z","timestamp":1770813702994,"version":"3.50.1"},"reference-count":74,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["15\/188\/42"],"award-info":[{"award-number":["15\/188\/42"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title>\n<jats:p>Procalcitonin is a biomarker specific for bacterial infection, with a more rapid response than other commonly used biomarkers, such as C-reactive protein, but it is not routinely used in the National Health Service.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-2\"><jats:title>Objective<\/jats:title>\n<jats:p>To determine if using a procalcitonin-guided algorithm may safely reduce duration of antibiotic therapy compared to standard of care in hospitalised children with suspected or confirmed infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-3\"><jats:title>Design<\/jats:title>\n<jats:p>A pragmatic, multicentre, open-label, parallel two-arm, individually randomised controlled trial with internal pilot phase, qualitative study and health economic evaluations.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-4\"><jats:title>Setting<\/jats:title>\n<jats:p>Paediatric wards or paediatric intensive care units within children\u2019s hospitals (<jats:italic>n<\/jats:italic>\u2005=\u20056) and district general hospitals (<jats:italic>n<\/jats:italic>\u2005=\u20059) in the United Kingdom.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-5\"><jats:title>Participants<\/jats:title>\n<jats:p>Children aged between 72 hours and 18 years admitted to hospital and being treated with intravenous antibiotics for suspected or confirmed bacterial infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-6\"><jats:title>Interventions<\/jats:title>\n<jats:p>Procalcitonin-guided algorithm versus usual standard care alone.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-7\"><jats:title>Main outcome measures<\/jats:title>\n<jats:p>Coprimary outcomes were duration of intravenous antibiotic use and a composite safety measure.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-8\"><jats:title>Results<\/jats:title>\n<jats:p>Between 11 June 2018 and 12 October 2022, 1949 children were recruited: 977 to the procalcitonin group [427 female (43.7%), 550 male (56.3%)], and 972 to the usual care group [478 female (49.2%), 494 male (50.8%)]. Duration of intravenous antibiotics was not significantly different between the procalcitonin group (median 96.0 hours) and the usual care group (median 99.7 hours) [hazard ratio\u2005=\u20050.96 (0.87, 1.05)], and the procalcitonin-guided algorithm was non-inferior to usual care [risk difference\u2005=\u2005\u22120.81% (95% confidence interval upper bound 1.11%)]. At clinical review, a procalcitonin result was available for 81.8% of the time, which was considered as part of clinical decision-making 66.6% of the time, and the algorithm was adhered to 57.2% of the time. Incremental cost-effectiveness ratio per duration of intravenous antibiotics hour avoided from bootstrapped samples was \u00a3467.62 per intravenous antibiotic hour avoided. Cost analysis of complete cases was also higher in the procalcitonin arm for all age groups, and for children aged 5 years and over. The intervention is not cost-effective as it is more expensive with no significant improvement in intravenous antibiotic duration.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-9\"><jats:title>Limitations<\/jats:title>\n<jats:p>Robust antimicrobial stewardship programmes were already implemented in the lead recruiting sites, and adherence to the algorithm was poor. Clinicians may be reluctant to adhere to biomarker-guided algorithms, due to unfamiliarity with interpreting the test result.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-10\"><jats:title>Conclusions<\/jats:title>\n<jats:p>In children hospitalised with confirmed or suspected bacterial infection, the addition of a procalcitonin-guided algorithm to usual care is non-inferior in terms of safety, but does not reduce duration of intravenous antibiotics, and is not cost-effective. In the presence of robust antimicrobial stewardship programmes to reduce antibiotic use, a procalcitonin-guided algorithm may offer little added value.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-11\"><jats:title>Future work<\/jats:title>\n<jats:p>Future trials must include an implementation framework to improve trial intervention fidelity, and repeated cycles of education and training to facilitate implementation of biomarker-guided algorithms into routine clinical care.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-12\"><jats:title>Trial registration<\/jats:title>\n<jats:p>This trial is registered as ISRCTN11369832.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-13\"><jats:title>Funding<\/jats:title>\n<jats:p>This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 15\/188\/42) and is published in full in <jats:italic>Health Technology Assessment<\/jats:italic>; Vol. 29, No. 16. See the NIHR Funding and Awards website for further award information.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/mbva3675","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T07:30:31Z","timestamp":1747639831000},"page":"1-125","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-2492","authenticated-orcid":true,"given":"Cherry-Ann","family":"Waldron","sequence":"first","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-9696","authenticated-orcid":true,"given":"Philip","family":"Pallmann","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-2170","authenticated-orcid":true,"given":"Simon","family":"Schoenbuchner","sequence":"additional","affiliation":[{"name":"Division of Population Medicine, School of Medicine, Cardiff University, Heath Park, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7073-7724","authenticated-orcid":true,"given":"Debbie","family":"Harris","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8263-7130","authenticated-orcid":true,"given":"Lucy","family":"Brookes-Howell","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6219-219X","authenticated-orcid":true,"given":"C\u00e9u","family":"Mateus","sequence":"additional","affiliation":[{"name":"Division of Health Research, Lancaster University, Lancaster, UK"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2941-9125","authenticated-orcid":true,"given":"Jolanta","family":"Bernatoniene","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Hospital for Children, Bristol, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-0769","authenticated-orcid":true,"given":"Katrina","family":"Cathie","sequence":"additional","affiliation":[{"name":"NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-7642","authenticated-orcid":true,"given":"Saul N","family":"Faust","sequence":"additional","affiliation":[{"name":"NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2709-900X","authenticated-orcid":true,"given":"Josie","family":"Henley","sequence":"additional","affiliation":[{"name":"School of Social Sciences, Cardiff University, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5042-4368","authenticated-orcid":true,"given":"Lucy","family":"Hinds","sequence":"additional","affiliation":[{"name":"Sheffield Children\u2019s NHS Foundation Trust, Sheffield, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-8631","authenticated-orcid":true,"given":"Kerry","family":"Hood","sequence":"additional","affiliation":[{"name":"College of Biomedical Life Sciences, Cardiff University, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3627-7218","authenticated-orcid":true,"given":"Chao","family":"Huang","sequence":"additional","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}]},{"given":"Sarah","family":"Jones","sequence":"additional","affiliation":[{"name":"Involve Network, Health and Care Research Wales, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5640-0300","authenticated-orcid":true,"given":"Sarah","family":"Kotecha","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1973-8286","authenticated-orcid":true,"given":"Sarah","family":"Milosevic","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-729X","authenticated-orcid":true,"given":"Helen","family":"Nabwera","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6329-0496","authenticated-orcid":true,"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[{"name":"NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0703-9114","authenticated-orcid":true,"given":"St\u00e9phane","family":"Paulus","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-875X","authenticated-orcid":true,"given":"Colin VE","family":"Powell","sequence":"additional","affiliation":[{"name":"Division of Population Medicine, School of Medicine, Cardiff University, Heath Park, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-234X","authenticated-orcid":true,"given":"Jenny","family":"Preston","sequence":"additional","affiliation":[{"name":"NIHR Alder Hey Clinical Research Facility, Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-001X","authenticated-orcid":true,"given":"Huasheng","family":"Xiang","sequence":"additional","affiliation":[{"name":"Management School, Lancaster University, Lancaster, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-2786","authenticated-orcid":true,"given":"Emma","family":"Thomas-Jones","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-7726","authenticated-orcid":true,"given":"Enitan D","family":"Carrol","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, UK"}]}],"member":"6221","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"key2025051912544900_ref1-bib1","doi-asserted-by":"crossref","first-page":"e047490","DOI":"10.1136\/bmjopen-2020-047490","article-title":"Biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection (BATCH): protocol for a randomised controlled trial","volume":"12","author":"Waldron","year":"2022","journal-title":"BMJ Open"},{"key":"key2025051912544900_ref2-bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"key2025051912544900_ref3-bib3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"key2025051912544900_ref4-bib4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s001340051288","article-title":"Use of antibiotics in pediatric intensive care and potential savings","volume":"26","author":"Fischer","year":"2000","journal-title":"Intensive Care Med"},{"key":"key2025051912544900_ref5-bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jama.1996.03530270074035","article-title":"Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership","volume":"275","author":"Goldmann","year":"1996","journal-title":"JAMA"},{"key":"key2025051912544900_ref6-bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-8579(02)00047-X","article-title":"Procalcitonin as a marker of sepsis","volume":"20","author":"Carrol","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"key2025051912544900_ref7-bib7","volume-title":"Procalcitonin Testing for Diagnosing and Monitoring Sepsis (ADVIA Centaur BRAHMS PCT Assay, BRAHMS PCT Sensitive Kryptor Assay, Elecsys BRAHMS PCT Assay, LIAISON BRAHMS PCT Assay and VIDAS BRAHMS PCT Assay)","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key2025051912544900_ref8-bib8","volume-title":"Tackling Antimicrobial Resistance 2019\u20132024. The UK\u2019s Five-Year National Action Plan. 2019 to 2024","author":"Department of Health","year":"2019"},{"key":"key2025051912544900_ref9-bib9","volume-title":"Contained and Controlled. The UK\u2019s 20-Year Vision for Antimicrobial Resistance","author":"Department of Health","year":"2019"},{"key":"key2025051912544900_ref10-bib10","volume-title":"Guidance: Start Smart Then Focus: Antimicrobial Stewardship Toolkit for Inpatient Care Settings","author":"UK Health Security Agency","year":"2023"},{"key":"key2025051912544900_ref12-bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/QCO.0000000000000449","article-title":"The impact of paediatric antimicrobial stewardship programmes on patient outcomes","volume":"31","author":"Patel","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"key2025051912544900_ref13-bib13","doi-asserted-by":"crossref","first-page":"e0246027","DOI":"10.1371\/journal.pone.0246027","article-title":"Procalcitonin, C-reactive protein, neutrophil gelatinase-associated lipocalin, resistin and the APTT waveform for the early diagnosis of serious bacterial infection and prediction of outcome in critically ill children","volume":"16","author":"Nielsen","year":"2021","journal-title":"PLOS One"},{"key":"key2025051912544900_ref14-bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcrc.2016.04.007","article-title":"Early procalcitonin kinetics and appropriateness of empirical antimicrobial therapy in critically ill patients: a prospective observational study","volume":"34","author":"Tr\u00e1sy","year":"2016","journal-title":"J Crit Care"},{"key":"key2025051912544900_ref15-bib15","doi-asserted-by":"crossref","first-page":"1758501","DOI":"10.1155\/2016\/1758501","article-title":"Serum procalcitonin and procalcitonin clearance as a prognostic biomarker in patients with severe sepsis and septic shock","volume":"2016","author":"Huang","year":"2016","journal-title":"Biomed Res Int"},{"key":"key2025051912544900_ref16-bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19960","article-title":"Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis","volume":"19","author":"Westwood","year":"2015","journal-title":"Health Technol Assess"},{"key":"key2025051912544900_ref17-bib17","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S1473-3099(16)30024-X","article-title":"Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines","volume":"16","author":"McMullan","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key2025051912544900_ref18-bib18","doi-asserted-by":"crossref","first-page":"ofad520","DOI":"10.1093\/ofid\/ofad520","article-title":"Procalcitonin monitoring and antibiotic duration in presumed lower respiratory tract infections: a propensity score-matched cohort across the veterans health administration","volume":"10","author":"Heren","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"key2025051912544900_ref19-bib19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cmi.2022.08.026","article-title":"Use of biomarkers to individualize antimicrobial therapy duration: a narrative review","volume":"29","author":"Scott","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"key2025051912544900_ref20-bib20","doi-asserted-by":"crossref","first-page":"e0220686","DOI":"10.1371\/journal.pone.0220686","article-title":"Procalcitonin to stop antibiotics after cardiovascular surgery in a pediatric intensive care unit \u2013 the PROSACAB study","volume":"14","author":"Bobillo-Perez","year":"2019","journal-title":"PLOS One"},{"key":"key2025051912544900_ref21-bib21","doi-asserted-by":"crossref","first-page":"e1003208","DOI":"10.1371\/journal.pmed.1003208","article-title":"Variation in antibiotic prescription rates in febrile children presenting to emergency departments across Europe (MOFICHE): a multicentre observational study","volume":"17","author":"Hagedoorn","year":"2020","journal-title":"PLOS Med"},{"key":"key2025051912544900_ref23-bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2352-4642(20)30304-7","article-title":"A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process","volume":"5","author":"Harwood","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"key2025051912544900_ref24-bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/bmj.330.7495.843","article-title":"Treatment allocation by minimisation","volume":"330","author":"Altman","year":"2005","journal-title":"BMJ"},{"key":"key2025051912544900_ref25-bib25","doi-asserted-by":"crossref","first-page":"e28096","DOI":"10.1371\/journal.pone.0028096","article-title":"Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool","volume":"6","author":"Gallagher","year":"2011","journal-title":"PLOS One"},{"key":"key2025051912544900_ref26-bib26","volume-title":"Young People Improving Research","author":"Generation"},{"key":"key2025051912544900_ref27-bib27","doi-asserted-by":"crossref","first-page":"e20162853","DOI":"10.1542\/peds.2016-2853","article-title":"Predicting risk of serious bacterial infections in febrile children in the emergency department","volume":"140","author":"Irwin","year":"2017","journal-title":"Pediatrics"},{"key":"key2025051912544900_ref28-bib28","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open- label trial","volume":"16","author":"de Jong","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key2025051912544900_ref29-bib29","unstructured":"Paediatric Intensive Care Audit Network (PICANet). Annual Report: Healthcare Quality Improvement Partnership. 2015. Paediatric Intensive Care Audit Network. PICANet Annual Report 2015\u20132017. Healthcare Quality Improvement Partnership; 2015."},{"key":"key2025051912544900_ref30-bib30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/11599120-000000000-00000","article-title":"Valuation of the Child Health Utility 9D Index","volume":"30","author":"Stevens","year":"2012","journal-title":"PharmacoEconomics"},{"key":"key2025051912544900_ref31-bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1473-3099(18)30289-5","article-title":"Use of co-primary outcomes for trials of antimicrobial stewardship interventions","volume":"18","author":"Gillespie","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key2025051912544900_ref32-bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/archdischild-2016-310494","article-title":"Predictors of fever-related admissions to a paediatric assessment unit, ward and reattendances in a South London emergency department: the CABIN 2 study","volume":"102","author":"Bustinduy","year":"2017","journal-title":"Arch Dis Child"},{"key":"key2025051912544900_ref33-bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PCC.0000000000001826","article-title":"Procalcitonin and other common biomarkers do not reliably identify patients at risk for bacterial infection after congenital heart surgery","volume":"20","author":"D\u2019Souza","year":"2019","journal-title":"Pediatr Crit Care Med"},{"key":"key2025051912544900_ref34-bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/009286150704100105","article-title":"Multiple co\u2010primary endpoints: medical and statistical solutions: a report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America","volume":"41","author":"Offen","year":"2007","journal-title":"Drug Information J"},{"key":"key2025051912544900_ref35-bib35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s13063-022-06956-9","article-title":"Biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: statistical analysis plan for the BATCH trial and PRECISE sub-study","volume":"24","author":"Schoenbuchner","year":"2023","journal-title":"Trials"},{"key":"key2025051912544900_ref36-bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jsp.2015.12.006","article-title":"Beyond intent to treat (ITT): a complier average causal effect (CACE) estimation primer","volume":"1","author":"Peugh","year":"2017","journal-title":"J Sch Psychol"},{"key":"key2025051912544900_ref37-bib37","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLOS Med"},{"key":"key2025051912544900_ref38-bib38","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"key":"key2025051912544900_ref39-bib39","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini","year":"2001","journal-title":"Ann Stat"},{"key":"key2025051912544900_ref40-bib40","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/1536867X1301300304","article-title":"Computing adjusted risk ratios and risk differences in Stata","volume":"13","author":"Norton","year":"2013","journal-title":"Stata J"},{"key":"key2025051912544900_ref41-bib41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13063-020-4070-4","article-title":"Handling an uncertain control group event risk in non\u2010inferiority trials: non\u2010inferiority frontiers and the power\u2010stabilising transformation","volume":"21","author":"Quartagno","year":"2020","journal-title":"Trials"},{"key":"key2025051912544900_ref42-bib42","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1002\/sim.6181","article-title":"Identification and estimation of survivor average causal effects","volume":"33","author":"Tchetgen Tchetgen","year":"2014","journal-title":"Stat Med"},{"key":"key2025051912544900_ref43-bib43","doi-asserted-by":"crossref","first-page":"h1258","DOI":"10.1136\/bmj.h1258","article-title":"Process evaluation of complex interventions: medical research council guidance","volume":"350","author":"Moore","year":"2015","journal-title":"BMJ"},{"key":"key2025051912544900_ref44-bib44","doi-asserted-by":"crossref","first-page":"a1655","DOI":"10.1136\/bmj.a1655","article-title":"Developing and evaluating complex interventions: the new medical research council guidance","volume":"337","author":"Craig","year":"2008","journal-title":"BMJ"},{"key":"key2025051912544900_ref45-bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40814-015-0026-y","article-title":"Maximising the impact of qualitative research in feasibility studies for randomised controlled trials: guidance for researchers","volume":"1","author":"O\u2019Cathain","year":"2015","journal-title":"Pilot Feasibility Stud"},{"key":"key2025051912544900_ref46-bib46","volume-title":"Qualitative Research Practice: A Guide for Social Science Students and Researchers","author":"Ritchie","year":"2003"},{"key":"key2025051912544900_ref47-bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2288-13-117","article-title":"Using the framework method for the analysis of qualitative data in multi-disciplinary health research","volume":"13","author":"Gale","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"key2025051912544900_ref48-bib48","doi-asserted-by":"crossref","first-page":"F283","DOI":"10.1136\/adc.2005.085449","article-title":"Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram","volume":"91","author":"Turner","year":"2006","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"key2025051912544900_ref49-bib49","first-page":"23","article-title":"Dynamics in levels of procalcitonin in healthy term newborns during the first 24 hours of life","volume":"52","author":"Krasteva","year":"2013","journal-title":"Akush Ginekol (Sofiia)"},{"key":"key2025051912544900_ref50-bib50","first-page":"81","article-title":"Physiological changes in serum procalcitonin concentrations in premature infants early after birth","volume":"15","author":"Liu","year":"2013","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"key2025051912544900_ref51-bib51","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/clinchem\/46.10.1583","article-title":"Serum procalcitonin concentrations in term delivering mothers and their healthy offspring: a longitudinal study","volume":"46","author":"Assumma","year":"2000","journal-title":"Clin Chem"},{"key":"key2025051912544900_ref52-bib52","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/tp-20-127","article-title":"Diagnostic utility of procalcitonin as a biomarker for late-onset neonatal sepsis","volume":"9","author":"Liu","year":"2020","journal-title":"Transl Pediatr"},{"key":"key2025051912544900_ref53-bib53","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00011-013-0661-9","article-title":"Inflammatory mediators of systemic inflammation in neonatal sepsis","volume":"62","author":"Sugitharini","year":"2013","journal-title":"Inflamm Res"},{"key":"key2025051912544900_ref54-bib54","doi-asserted-by":"crossref","first-page":"F368","DOI":"10.1136\/fetalneonatal-2010-194100","article-title":"Procalcitonin in detecting neonatal nosocomial sepsis","volume":"97","author":"Auriti","year":"2012","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"key2025051912544900_ref55-bib55","doi-asserted-by":"crossref","first-page":"e854","DOI":"10.1016\/j.ijid.2011.09.007","article-title":"Procalcitonin measurement at 24 hours of age may be helpful in the prompt diagnosis of early-onset neonatal sepsis","volume":"15","author":"Altunhan","year":"2011","journal-title":"Int J Infect Dis"},{"key":"key2025051912544900_ref56-bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/1120009X.2007.11782442","article-title":"Biochemical markers for the early assessment of neonatal sepsis: the role of procalcitonin","volume":"19","author":"Mussap","year":"2007","journal-title":"J Chemother"},{"key":"key2025051912544900_ref57-bib57","doi-asserted-by":"crossref","first-page":"m2215","DOI":"10.1136\/bmj.m2215","article-title":"Non-adherence in non-inferiority trials: pitfalls and recommendations","volume":"370","author":"Mo","year":"2020","journal-title":"BMJ"},{"key":"key2025051912544900_ref58-bib58","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/MLR.0b013e31819bc064","article-title":"Microcosting quantity data collection methods","volume":"47","author":"Frick","year":"2009","journal-title":"Med Care"},{"key":"key2025051912544900_ref59-bib59","volume-title":"Serum Procalcitonin Testing in Medical Admissions (for Adults Only)","author":"Improving Antimicrobial Prescribing Group","year":"2017"},{"key":"key2025051912544900_ref60-bib60","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"PharmacoEconomics"},{"key":"key2025051912544900_ref61-bib61","article-title":"ICE: Stata module for multiple imputation of missing values","author":"Royston","journal-title":"Statistical Software Components S446602, Boston College Department of Economics"},{"key":"key2025051912544900_ref62-bib62","volume-title":"Employee Earnings in the UK: 2021","author":"Office of National Statistics","year":"2021"},{"key":"key2025051912544900_ref63-bib63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1077558705285298","article-title":"Self-reported utilization of health care services: improving measurement and accuracy","volume":"63","author":"Bhandari","year":"2006","journal-title":"Med Care Res Rev"},{"key":"key2025051912544900_ref64-bib64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1017\/S026646230200051X","article-title":"The accuracy of self-reported healthcare resource utilization in health economic studies","volume":"18","author":"Petrou","year":"2002","journal-title":"Int J Technol Assess Health Care"},{"key":"key2025051912544900_ref65-bib65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated consolidated framework for implementation research based on user feedback","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement Sci"},{"key":"key2025051912544900_ref66-bib66","doi-asserted-by":"crossref","first-page":"26152","DOI":"10.3402\/qhw.v9.26152","article-title":"What can \u2018thematic analysis\u2019 offer health and wellbeing researchers?","volume":"9","author":"Braun","year":"2014","journal-title":"Int J Qual Stud Health Well-being"},{"key":"key2025051912544900_ref67-bib67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13012-016-0436-0","article-title":"Discrepancies between qualitative and quantitative evaluation of randomised controlled trial results: achieving clarity through mixed methods triangulation","volume":"11","author":"Tonkin-Crine","year":"2016","journal-title":"Implement Sci"},{"key":"key2025051912544900_ref69-bib69","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(17)31444-7","article-title":"Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns)","volume":"390","author":"Stocker","year":"2017","journal-title":"Lancet"},{"key":"key2025051912544900_ref70-bib70","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial","volume":"375","author":"Bouadma","year":"2010","journal-title":"Lancet"},{"key":"key2025051912544900_ref71-bib71","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/23744235.2022.2037701","article-title":"Antibiotics duration guided by biomarkers in hospitalized adult patients; a systematic review and meta-analysis","volume":"54","author":"Elnajdy","year":"2022","journal-title":"Infect Dis"},{"key":"key2025051912544900_ref72-bib72","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s13054-023-04677-2","article-title":"Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival \u2013 a systematic review and meta-analysis","volume":"27","author":"Papp","year":"2023","journal-title":"Crit Care"},{"key":"key2025051912544900_ref73-bib73","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhin.2020.05.030","article-title":"Paediatric antimicrobial stewardship programmes in the UK\u2019s regional children\u2019s hospitals","volume":"105","author":"Vergnano","year":"2020","journal-title":"J Hosp Infect"},{"key":"key2025051912544900_ref74-bib74","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/S1473-3099(22)00726-5","article-title":"Multinational consensus antimicrobial stewardship recommendations for children managed in hospital settings","volume":"23","author":"McMullan","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"key2025051912544900_ref75-bib75","doi-asserted-by":"crossref","first-page":"e063424","DOI":"10.1136\/bmjopen-2022-063424","article-title":"PROcalcitonin and NEWS2 evaluation for Timely identification of sepsis and Optimal use of antibiotics in the emergency department (PRONTO): protocol for a multicentre, open-label, randomised controlled trial","volume":"12","author":"Euden","year":"2022","journal-title":"BMJ Open"},{"key":"key2025051912544900_ref76-bib76","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/17511437231169193","article-title":"BiomArker-guided Duration of Antibiotic treatment in hospitalised Patients with suspecTed Sepsis (ADAPT-Sepsis): a protocol for a multicentre randomised controlled trial","volume":"24","author":"Dark","year":"2023","journal-title":"J Intensive Care Soc"},{"key":"key2025051912544900_ref77-bib77","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1186\/s12913-023-09559-5","article-title":"A qualitative interview study applying the COM-B model to explore how hospital-based trainers implement antimicrobial stewardship education and training in UK hospital-based care","volume":"23","author":"Turner","year":"2023","journal-title":"BMC Health Serv Res"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047902","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/MBVA3675\/MBVA3675.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T07:30:48Z","timestamp":1747639848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/MBVA3675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":74,"alternative-id":["10.3310\/MBVA3675"],"URL":"https:\/\/doi.org\/10.3310\/mbva3675","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"09-2017","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"02-2024","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"10-2024","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}